Asim Armagan Aydin, Ahmet Unlu, Neslihan Atabek, Erkan Kayikcioglu, Kamuran Yuceer, Gizem Zorlu Gorgulugil, Ridvan Yavuz, Mehmet Acun, Ece Ulukal Karanci, Banu Ozturk, Mustafa Yildiz
{"title":"Gustave Roussy免疫评分作为预测异柠檬酸脱氢酶野生型胶质母细胞瘤患者生存的一种新的生物标志物。","authors":"Asim Armagan Aydin, Ahmet Unlu, Neslihan Atabek, Erkan Kayikcioglu, Kamuran Yuceer, Gizem Zorlu Gorgulugil, Ridvan Yavuz, Mehmet Acun, Ece Ulukal Karanci, Banu Ozturk, Mustafa Yildiz","doi":"10.1080/14737140.2025.2555467","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Isocitrate dehydrogenase (IDH) wild-type (wt) glioblastoma is a biologically aggressive adult-type diffuse glioma with poor prognosis. Gustave Roussy Immune Score (GRIm-Score), reflecting systemic inflammation and nutritional status, has shown prognostic relevance in several cancers. Its prognostic value in IDH-wt glioblastoma remains undefined.</p><p><strong>Methods: </strong>This retrospective single-center study included 186 patients with histologically confirmed IDH-wt glioblastoma. GRIm-Score was calculated using pretreatment NLR, albumin, and lactate dehydrogenase (LDH) levels. Patients were grouped into low- and high-risk categories. Associations with overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan-Meier and Cox regression analyses. Correlations with other inflammation-based indices, such as PILE, CAR, and PIV, were also examined.</p><p><strong>Results: </strong>A high GRIm-Score was significantly associated with reduced OS and PFS. Patients with higher scores more frequently exhibited poor prognostic features, including advanced age, worse ECOG performance, limited treatment response, and subtotal resection. Multivariate analysis identified GRIm-Score as an independent prognostic factor, particularly when analyzed alongside CAR and PIV. Strong correlations were observed between GRIm-Score and other immuno-nutritional markers.</p><p><strong>Conclusions: </strong>GRIm-Score is a simple and reliable prognostic indicator in IDH-wt glioblastoma. Its routine use may improve risk stratification and inform therapeutic decisions. Further prospective multicenter validation is warranted.</p>","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-8"},"PeriodicalIF":2.8000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Gustave Roussy immune score as a novel biomarker for predicting survival in patients with isocitrate dehydrogenase wild-type glioblastoma treated with the Stupp protocol.\",\"authors\":\"Asim Armagan Aydin, Ahmet Unlu, Neslihan Atabek, Erkan Kayikcioglu, Kamuran Yuceer, Gizem Zorlu Gorgulugil, Ridvan Yavuz, Mehmet Acun, Ece Ulukal Karanci, Banu Ozturk, Mustafa Yildiz\",\"doi\":\"10.1080/14737140.2025.2555467\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Isocitrate dehydrogenase (IDH) wild-type (wt) glioblastoma is a biologically aggressive adult-type diffuse glioma with poor prognosis. Gustave Roussy Immune Score (GRIm-Score), reflecting systemic inflammation and nutritional status, has shown prognostic relevance in several cancers. Its prognostic value in IDH-wt glioblastoma remains undefined.</p><p><strong>Methods: </strong>This retrospective single-center study included 186 patients with histologically confirmed IDH-wt glioblastoma. GRIm-Score was calculated using pretreatment NLR, albumin, and lactate dehydrogenase (LDH) levels. Patients were grouped into low- and high-risk categories. Associations with overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan-Meier and Cox regression analyses. Correlations with other inflammation-based indices, such as PILE, CAR, and PIV, were also examined.</p><p><strong>Results: </strong>A high GRIm-Score was significantly associated with reduced OS and PFS. Patients with higher scores more frequently exhibited poor prognostic features, including advanced age, worse ECOG performance, limited treatment response, and subtotal resection. Multivariate analysis identified GRIm-Score as an independent prognostic factor, particularly when analyzed alongside CAR and PIV. Strong correlations were observed between GRIm-Score and other immuno-nutritional markers.</p><p><strong>Conclusions: </strong>GRIm-Score is a simple and reliable prognostic indicator in IDH-wt glioblastoma. Its routine use may improve risk stratification and inform therapeutic decisions. Further prospective multicenter validation is warranted.</p>\",\"PeriodicalId\":12099,\"journal\":{\"name\":\"Expert Review of Anticancer Therapy\",\"volume\":\" \",\"pages\":\"1-8\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Anticancer Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14737140.2025.2555467\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2025.2555467","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
The Gustave Roussy immune score as a novel biomarker for predicting survival in patients with isocitrate dehydrogenase wild-type glioblastoma treated with the Stupp protocol.
Background: Isocitrate dehydrogenase (IDH) wild-type (wt) glioblastoma is a biologically aggressive adult-type diffuse glioma with poor prognosis. Gustave Roussy Immune Score (GRIm-Score), reflecting systemic inflammation and nutritional status, has shown prognostic relevance in several cancers. Its prognostic value in IDH-wt glioblastoma remains undefined.
Methods: This retrospective single-center study included 186 patients with histologically confirmed IDH-wt glioblastoma. GRIm-Score was calculated using pretreatment NLR, albumin, and lactate dehydrogenase (LDH) levels. Patients were grouped into low- and high-risk categories. Associations with overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan-Meier and Cox regression analyses. Correlations with other inflammation-based indices, such as PILE, CAR, and PIV, were also examined.
Results: A high GRIm-Score was significantly associated with reduced OS and PFS. Patients with higher scores more frequently exhibited poor prognostic features, including advanced age, worse ECOG performance, limited treatment response, and subtotal resection. Multivariate analysis identified GRIm-Score as an independent prognostic factor, particularly when analyzed alongside CAR and PIV. Strong correlations were observed between GRIm-Score and other immuno-nutritional markers.
Conclusions: GRIm-Score is a simple and reliable prognostic indicator in IDH-wt glioblastoma. Its routine use may improve risk stratification and inform therapeutic decisions. Further prospective multicenter validation is warranted.
期刊介绍：
Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches.
Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care.
Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections:
Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results
Article Highlights – an executive summary of the author’s most critical points.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
